SAN DIEGO—(BUSINESS WIRE)—Aug. 8, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system disorders,today announced that it intends to offer and sell, subject to market andother conditions, $200,000,000 of its common stock in an underwrittenpublic offering. There can be no assurance as to whether or when theoffering may be completed, or as to the actual size or terms of theoffering.
J.P. Morgan Securities LLC, Goldman, Sachs & Co. and BofA Merrill Lynchare acting as the joint book-running managers for the offering. ACADIAintends to grant the underwriters a 30-day option to purchase anadditional $30,000,000 of its common stock.
The shares of common stock described above are being offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective on March 3, 2014. A preliminary prospectus supplement relatedto the offering will be filed with the SEC and will be available on theSEC’s website located at http://www.sec.gov.Copies of the preliminary prospectus supplement and the accompanyingprospectus related to this offering, when available, may be obtainedfrom J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866)803-9204, or by email to: prospectus-eq_fi@jpmchase.com,or from Goldman, Sachs & Co., Attention: Prospectus Department, 200 WestStreet, New York, NY 10282, or by telephone at (866) 471-2526, or byemail to: prospectus-ny@ny.email.gs.com,or from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rdfloor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or byemail to: dg.prospectus_requests@baml.com.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature, including statements related to the proposed offering of commonstock by ACADIA, are forward-looking statements. These statements areonly predictions based on current information and expectations andinvolve a number of risks and uncertainties. Actual events or resultsmay differ materially from those projected in any of such statements dueto various factors, including market risks and uncertainties and thesatisfaction of customary closing conditions for an offering ofsecurities. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2015as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, SeniorDirector, Investor Relations
(858) 558-2871